Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44395   clinical trials with a EudraCT protocol, of which   7407   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,395 result(s) found. Displaying page 1,663 of 2,220.
    «« First « Previous 1659  1660  1661  1662  1663  1664  1665  1666  1667  Next» Last»»
    EudraCT Number: 2019-000794-23 Sponsor Protocol Number: 49RC19_0034 Start Date*: 2019-07-26
    Sponsor Name:CHU ANGERS
    Full Title: AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé en simple aveugle comparant les effets neurocognitifs du rivaroxaban par rapport à un antagoniste de la vitamine K
    Medical condition: fibrillation atriale non valvulaire
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    20.0 10007541 - Cardiac disorders 10007521 Cardiac arrhythmias HLGT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001387-28 Sponsor Protocol Number: NL73559.091.20 Start Date*: 2020-06-22
    Sponsor Name:Radboud University Medical Center
    Full Title: 18F-PSMA-1007 PET to detect primary prostate cancer: a comparative study with mpMRI and correlation to histopathology.
    Medical condition: 75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005347-79 Sponsor Protocol Number: UMCN-AKF-21.07 Start Date*: 2022-03-31
    Sponsor Name:Radboud University Medical Center
    Full Title: The influence of having bariatric surgery on the pharmacokinetics, safety and efficacy of the novel non-nucleoside reverse transcriptase inhibitor doravirine (LABRADOR)
    Medical condition: HIV plus bariatric surgery
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    21.1 100000004865 10068900 Bariatric surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001802-30 Sponsor Protocol Number: TMP-3001-2020-30 Start Date*: 2021-10-28
    Sponsor Name:Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP)
    Full Title: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus (BeCarma)
    Medical condition: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002507-18 Sponsor Protocol Number: CSET2019/2955 Start Date*: 2020-04-10
    Sponsor Name:Gustave Roussy
    Full Title: Efficacy and feasibility of pasireotide to reduce clinically relevant digestive leakage after complete cytoreductive surgery (CRS) plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for perito...
    Medical condition: Primary and secondary peritoneal malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068069 Peritoneal carcinomatosis LLT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004501-32 Sponsor Protocol Number: NL51240.018.14 Start Date*: 2014-12-11
    Sponsor Name:Academic Medical Center
    Full Title: Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's disease comparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treetment...
    Medical condition: Patients with advanced PD who's motor symptoms — severe response fluctuations, dyskinesias, painful dystonia and / or bradykinesia — cannot be controlled despite optimal oral pharmacological therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002269-14 Sponsor Protocol Number: NL80263.018.21 Start Date*: 2022-08-11
    Sponsor Name:AMC, Cardiovascular Sciences
    Full Title: Dotatate to locate coronary plaques at high-risk of myocardial infarction
    Medical condition: Inflammatory atherosclerosis of the coronary arteries.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000702-30 Sponsor Protocol Number: 18.021 Start Date*: 2019-10-30
    Sponsor Name:Odense University Hospital
    Full Title: Fibromyalgia and Naltrexone: The FINAL study
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001917-35 Sponsor Protocol Number: NOX66-005 Start Date*: 2021-10-25
    Sponsor Name:Noxopharm Limited
    Full Title: A Phase 1b/2a Multicenter Study of NOX66 and External Beam Radiotherapy in Patients with Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
    Medical condition: Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-000842-36 Sponsor Protocol Number: Version128May2019 Start Date*: 2020-04-07
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: A Polatuzumab Vedotin Containing Chemo-Immunotherapeutic Regimen in Patients with Diffuse Large B-Cell Lymphoma Unsuitable for Full Dose R-CHOP Therapy
    Medical condition: Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002154-70 Sponsor Protocol Number: CP40559 Start Date*: 2019-10-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH IN...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.0 100000004862 10016790 Flu LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) ES (Ongoing) FI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-003309-79 Sponsor Protocol Number: MK-8591-024 Start Date*: 2021-04-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender...
    Medical condition: HIV Preexposure prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-000382-32 Sponsor Protocol Number: REP0121 Start Date*: 2021-08-16
    Sponsor Name:Dompé farmaceutici s.p.a.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastat...
    Medical condition: Cancer related fatigue in patients with locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082262 Chemotherapy fatigue LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000307-26 Sponsor Protocol Number: CeTMAd-VIH-2014 Start Date*: 2016-06-09
    Sponsor Name:Iniciativa Andaluza en Terapias Avanzadas-Fundación Pública Andaluza Progreso y Salud
    Full Title: Clinical trial Phase I/II, test of concept, double blind, randomized, controlled with placebo, to evalue the safety and efficiency of the treatment with expanded adult mesenchymal stem cells from a...
    Medical condition: Infection for HIV with controlled viral load and immunological discordant response
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10001509 AIDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-001984-21 Sponsor Protocol Number: 3/013/13 Start Date*: 2013-09-11
    Sponsor Name:University of Aberdeen & NHS Grampian
    Full Title: PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-002638-54 Sponsor Protocol Number: ALN-AS1-002 Start Date*: 2017-12-20
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Comple...
    Medical condition: Acute Intermittent Porphyria (AIP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000818 Acute intermittent porphyria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-005596-39 Sponsor Protocol Number: MPELONG Start Date*: 2022-09-07
    Sponsor Name:MAPS Europe B.V.
    Full Title: Long-Term Safety and Persistence of Effectiveness of Manualized MDMA Assisted Therapy for the Treatment of Posttraumatic Stress Disorder
    Medical condition: post-traumatic stress disorder (PTSD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004037-93 Sponsor Protocol Number: TRACE Start Date*: 2018-01-17
    Sponsor Name:Afdeling for Rygkirurgi, Led- og Bindevævssygdomme ; Rigshospitalet - Glostrup
    Full Title: TReat-to-tArget (T2T) with seCukinumab in axial spondyloarthritis. IdEntification of MRI and biochemical biomarkers for disease activity, treatment response and structural damage progression (the T...
    Medical condition: Axial spondyloarthritis and ankylosing spondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004600-17 Sponsor Protocol Number: T21 Start Date*: Information not available in EudraCT
    Sponsor Name:Royal College of Surgeons in Ireland
    Full Title: The use of Sildenafil in Neonates with Down Syndrome to Reduce Pulmonary Vascular Resistance.
    Medical condition: to assess the impact of oral sildenafil administration on echocardiography measurements of pulmonary vascular resistance in neonates with Down Syndrome without Congenital Heart Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10067285 Vascular resistance pulmonary increased PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005544-79 Sponsor Protocol Number: Beau_Resp_05_001 Start Date*: 2006-03-24
    Sponsor Name:The Clinical Research Centre, RCSI Education and Research Centre
    Full Title: Adalimumab (Humira) as add-on therapy in the treatment of patients with severe persistent therapy resistant asthma
    Medical condition: Severe Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1659  1660  1661  1662  1663  1664  1665  1666  1667  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 30 18:45:59 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA